Loading clinical trials...
Loading clinical trials...
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Conditions
Interventions
Lecanemab 2.5 mg/kg
Lecanemab 5.0 mg/kg
+5 more
Locations
169
United States
Facility #1
Birmingham, Alabama, United States
Facility #1
Phoenix, Arizona, United States
Facility #1
Tucson, Arizona, United States
Facility #1
Carson, California, United States
Facility #1
Lomita, California, United States
Facility #1
Long Beach, California, United States
Start Date
December 20, 2012
Primary Completion Date
December 10, 2024
Completion Date
December 10, 2024
Last Updated
March 4, 2026
NCT06159673
NCT07457138
NCT07033494
NCT07214727
NCT07422857
NCT06584357
Lead Sponsor
Eisai Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions